Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278918 | 0.90 | NPY5R (0.42) | HTR6ACLYAKT1NPY5RNOTUM | |
| SCHEMBL6808219 | 0.90 | CYP3A4 (0.47) | MMP2HTR6ACLYAKT1NPY5R | |
| SCHEMBL30733423 | 0.88 | KCNN4 (0.47) | KCNN4KCNA3OXTRAKR1B1MMP2 | |
| SCHEMBL17969882 | 0.85 | HTR6 (0.46) | KCNN4KCNA3OXTRAKR1B1MMP2 | |
| SCHEMBL25237931 | 0.84 | ACLY (0.41) | HTR6ACLYAKT1NPY5R | |
| SCHEMBL38332 | 0.81 | NPY5R (0.55) | NPY5RNOTUM | |
| SCHEMBL30051797 | 0.81 | NPY5R (0.55) | NPY5RNOTUM | |
| Hydrochloric Acid SCHEMBL7123289 | 0.80 | NPY5R (0.54) | NPY5RNOTUM | |
| Hydrochloric Acid SCHEMBL2888051 | 0.80 | NPY5R (0.54) | NPY5RNOTUM | |
| SCHEMBL737327 | 0.79 | NPY5R (0.50) | AKT1NPY5RNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| EP-2023924-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136605-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136605-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | HDAC1, BRDT, HDAC5 | KCNN4 2778/4885KCNA3 2952/4885OXTR 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.